脊髄性筋萎縮症治療の世界市場レポート2025年

脊髄性筋萎縮症治療の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR15.3%で90億2,000万米ドルに成長します。この将来の成長に拍車をかける要因としては、SMA有病率の継続的な上昇、最先端の遺伝子治療の承認拡大、早期治療をめぐる認知度の向上、科学研究への継続的な資金提供、新生児スクリーニングプログラムの拡大などが挙げられます。この期間に予想される主な動向には、遺伝子治療の技術革新の発展、個別化医療技術の採用、技術を利用した経口治療法の出現、新生児の早期診断スクリーニングの進展、併用療法手法の開発などがあります。

遺伝子治療への注目の高まりが脊髄性筋萎縮症（SMA）治療市場の成長を牽引すると予想されます。遺伝子治療には、病気の治療や予防のためにDNAやRNAといった人の遺伝物質を改変することが含まれます。このような注目の高まりは、遺伝子治療が欠陥のある遺伝子を直接改変したり置き換えたりすることで遺伝性疾患の根本原因に対処する能力を持ち、従来の治療法よりも長期的または永続的な治療効果をもたらす可能性があることが主な理由です。脊髄性筋萎縮症の治療、例えばonasemogene abeparvovec（Zolgensma）は、遺伝子治療を利用して、SMN1遺伝子の機能的コピーを提供する1回限りの標的を絞った解決策を提供しています。このアプローチは、SMA患者の運動機能と生活の質を著しく向上させる。例えば、2024年1月、米国遺伝子・細胞治療学会は、2023年第4四半期の第III相臨床試験中の遺伝子治療薬の数が前四半期に比べて10％増加したことを報告し、このような増加は2022年第3四半期以来初めてであることを示しました。この動向は、遺伝子治療への注目の高まりが脊髄性筋萎縮症治療市場を後押ししていることを浮き彫りにしています。

脊髄性筋萎縮症治療市場の主要企業は、運動機能を改善し病気の進行を遅らせるために、生存運動ニューロン2（SMN2）スプライシング修飾錠などの革新的な製剤を開発しています。これらの錠剤は、SMN2遺伝子のスプライシングを修正し、運動ニューロンの生存に不可欠な機能的SMNタンパク質の産生を促進するように設計された経口薬です。完全長のSMNタンパク質のレベルを増加させることにより、これらの治療薬は筋機能を改善し、疾患の進行を遅らせるのに役立ちます。例えば、2025年2月、米国のバイオテクノロジー企業であるジェネンテック社は、Evrysdi（risdiplam）錠剤の承認を米国食品医薬品局から取得しました。この錠剤は、SMAの治療に使用可能な最初で唯一の非侵襲的SMN2スプライシング修飾剤です。Evrysdiは、既存の経口剤と同様の有効性と安全性を持ち、さらに、室温保存が可能で、体重が20キログラム（44ポンド）を超える2歳以上の患者への投与が容易であるなどのその他の特典があり、利便性と疾患管理の柔軟性を高めています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の脊髄性筋萎縮症治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脊髄性筋萎縮症治療市場：成長率分析
• 世界の脊髄性筋萎縮症治療市場の実績：規模と成長, 2019-2024
• 世界の脊髄性筋萎縮症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の脊髄性筋萎縮症治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の脊髄性筋萎縮症治療市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤
• 理学療法
• 手術
• その他の治療法
• 世界の脊髄性筋萎縮症治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヴェルドニッヒ・ホフマン病
• 乳児脊髄性筋萎縮症（SMA）
• クーゲルベルク・ウェランダー病
• 成人脊髄性筋萎縮症（SMA）
• 世界の脊髄性筋萎縮症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 非経口
• 世界の脊髄性筋萎縮症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の脊髄性筋萎縮症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 在宅ケア
• 専門クリニック
• その他のエンドユーザー
• 世界の脊髄性筋萎縮症治療市場、薬剤、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• ヌシネルセン（スピンラザ）
• オナセムノゲン・アベパルボベック-シオイ（ゾルゲンスマ）
• リスディプラム（エヴリスディ）
• アンチセンスオリゴヌクレオチド
• 脊髄性筋萎縮症（SMN2）スプライシング修飾因子
• コルチコステロイド
• 支持療法
• 世界の脊髄性筋萎縮症治療市場、理学療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 作業療法
• 呼吸療法
• 水中療法
• 矯正サポート
• 移動補助装置
• 可動域運動
• 世界の脊髄性筋萎縮症治療市場、手術、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 脊椎固定手術
• 脊柱側弯症矯正手術
• 整形外科
• 胃瘻チューブの設置
• 気管切開
• 世界の脊髄性筋萎縮症治療市場、その他の治療、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養サポート
• 呼吸サポート
• 心理社会的支援とカウンセリング
• 遺伝カウンセリング
• 幹細胞療法

第7章 地域別・国別分析

• 世界の脊髄性筋萎縮症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の脊髄性筋萎縮症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脊髄性筋萎縮症治療市場：競合情勢
• 脊髄性筋萎縮症治療市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Chugai Pharmaceutical Co. Ltd Overview, Products and Services, Strategy and Financial Analysis
  • PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ionis Pharmaceuticals Inc.
• Ultragenyx Pharmaceutical Inc.
• Catalyst Pharmaceuticals Inc.
• BIOCAD INDIA PRIVATE LIMITED
• Cytokinetics Incorporated
• Voyager Therapeutics Inc.
• Scholar Rock Holding Corporation
• Genethon
• Exegenesis Bio Inc
• NMD Pharma A/S
• Biohaven Pharmaceutical Holding Company Ltd
• Alcyone Therapeutics Inc.
• Vybion Inc.
• Apteeus SAS
• Biophytis SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脊髄性筋萎縮症治療市場2029：新たな機会を提供する国
• 脊髄性筋萎縮症治療市場2029：新たな機会を提供するセグメント
• 脊髄性筋萎縮症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Spinal muscular atrophy (SMA) treatment encompasses medical therapies and interventions aimed at enhancing muscle strength, improving motor abilities, and elevating the quality of life for individuals affected by SMA. This genetic disorder is marked by the progressive degeneration of motor neurons located in the spinal cord and lower brainstem.

The primary treatment options for spinal muscular atrophy include medications, physical therapy, surgical procedures, and other therapeutic approaches. Medications play a crucial role in alleviating symptoms, boosting motor performance, and slowing the progression of the disease. These therapies address various SMA types such as Werdnig-Hoffmann disease, infantile SMA, Kugelberg-Welander disease, and adult-onset SMA. Drug administration routes include oral and parenteral methods, and these medications are dispensed through hospital pharmacies, retail pharmacies, and other distribution networks. The key end users of these treatments include hospitals, homecare providers, specialty clinics, and others.

The spinal muscular atrophy treatment market research report is one of a series of new publications from The Business Research Company that offer comprehensive data on the spinal muscular atrophy treatment market, including global industry size, regional market shares, key players and their market positioning, detailed segmentation, current market trends, potential opportunities, and other essential insights. This report presents an all-encompassing view of the industry, offering a detailed examination of the present landscape and future prospects.

The spinal muscular atrophy treatment market size has grown rapidly in recent years. It will grow from $4.41 billion in 2024 to $5.10 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. This expansion during the historical period was driven by a rising number of SMA cases, increased approvals of innovative gene therapies, heightened public awareness about early diagnosis and interventions, greater investment in R&D activities, and broader implementation of newborn screening initiatives.

The spinal muscular atrophy treatment market size is expected to see rapid growth in the next few years. It will grow to $9.02 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. Factors fueling this future growth include the ongoing rise in SMA prevalence, more approvals of cutting-edge gene therapies, amplified awareness surrounding early-stage treatment, continuous funding in scientific research, and an expanding reach of neonatal screening programs. Key trends expected in this period include improvements in gene therapy innovations, the adoption of personalized medicine techniques, the emergence of technology-enabled oral treatment options, progress in early diagnostic screening for newborns, and the development of combination therapy methodologies.

The increasing focus on gene therapy is expected to drive the growth of the spinal muscular atrophy (SMA) treatment market. Gene therapy involves modifying a person's genetic material, such as DNA or RNA, to treat or prevent diseases. This rising attention is largely due to gene therapy's ability to address the root cause of genetic disorders by directly modifying or replacing defective genes, offering potentially long-term or permanent therapeutic benefits over traditional treatments. Treatments for spinal muscular atrophy, such as onasemnogene abeparvovec (Zolgensma), utilize gene therapy to provide a one-time, targeted solution that delivers a functional copy of the SMN1 gene. This approach significantly enhances motor function and quality of life for patients with SMA. For example, in January 2024, the American Society of Gene and Cell Therapy reported a 10% increase in the number of gene therapies in Phase III trials in the fourth quarter of 2023 compared to the previous quarter, marking the first such rise since the third quarter of 2022. This trend highlights how the growing emphasis on gene therapy is boosting the spinal muscular atrophy treatment market.

Leading companies in the spinal muscular atrophy treatment market are developing innovative formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to improve motor function and slow disease progression. These tablets are oral medications designed to modify the splicing of the SMN2 gene to promote the production of functional SMN protein, which is vital for motor neuron survival. By increasing the levels of full-length SMN protein, these treatments help improve muscle function and decelerate disease advancement. For instance, in February 2025, Genentech, Inc., a U.S.-based biotechnology company, received approval from the U.S. Food and Drug Administration for its Evrysdi (risdiplam) tablet. This tablet is the first and only non-invasive SMN2 splicing modifier available for treating SMA. Evrysdi offers similar efficacy and safety to the existing oral solution, along with additional benefits such as room-temperature storage and easier administration for patients aged two years and older who weigh more than 44 pounds (20 kilograms), enhancing convenience and flexibility in managing the disease.

In January 2024, Voyager Therapeutics Inc., a U.S.-based biotechnology firm, entered a partnership with Novartis to advance gene therapies for neurological diseases. This collaboration aims to develop novel gene therapies for conditions such as Huntington's disease and spinal muscular atrophy by combining Voyager's TRACER capsid technology with Novartis's experience in gene therapy development and commercialization. Novartis, a pharmaceutical company headquartered in Switzerland, specializes in providing treatments for spinal muscular atrophy.

Major players in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., BIOCAD INDIA PRIVATE LIMITED, Cytokinetics Incorporated, Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc, NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Alcyone Therapeutics Inc., Vybion Inc., Apteeus SAS, Biophytis SA, and Ractigen Therapeutics.

North America was the largest region in the spinal muscular atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spinal muscular atrophy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spinal muscular atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spinal muscular atrophy treatment market consists of revenues earned by entities by providing services such as gene delivery services, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The spinal muscular atrophy treatment market also includes sales of spinraza, zolgensma, evrysdi, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Spinal Muscular Atrophy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on spinal muscular atrophy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for spinal muscular atrophy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The spinal muscular atrophy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Physical Therapy; Surgery; Other Treatments
• 2) By Type: Werdnig-Hoffmann Disease; Infant Spinal Muscular Atrophy; Kugelberg-Welander Disease; Adult Spinal Muscular Atrophy
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Medication: Nusinersen (Spinraza); Onasemnogene Abeparvovec-Xioi (Zolgensma); Risdiplam (Evrysdi); Antisense Oligonucleotides; Spinal Muscular Atrophy (SMN2) Splicing Modifiers; Corticosteroids; Supportive Medications
• 2) By Physical Therapy: Occupational Therapy; Respiratory Therapy; Aquatic Therapy; Orthotic Support; Assistive Mobility Devices; Range-Of-Motion Exercises
• 3) By Surgery: Spinal Fusion Surgery; Scoliosis Correction Surgery; Orthopedic Surgery; Gastrostomy Tube Placement; Tracheostomy
• 4) By Other Treatments: Nutritional Support; Respiratory Support; Psychosocial Support And Counseling; Genetic Counseling; Stem Cell Therapy
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Biogen Inc.; Chugai Pharmaceutical Co. Ltd; PTC Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Spinal Muscular Atrophy Treatment Market Characteristics

3. Spinal Muscular Atrophy Treatment Market Trends And Strategies

4. Spinal Muscular Atrophy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Spinal Muscular Atrophy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Spinal Muscular Atrophy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Spinal Muscular Atrophy Treatment Market Growth Rate Analysis
• 5.4. Global Spinal Muscular Atrophy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Spinal Muscular Atrophy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Spinal Muscular Atrophy Treatment Total Addressable Market (TAM)

6. Spinal Muscular Atrophy Treatment Market Segmentation

• 6.1. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Physical Therapy
• Surgery
• Other Treatments
• 6.2. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Werdnig-Hoffmann Disease
• Infant Spinal Muscular Atrophy (Sma)
• Kugelberg-Welander Disease
• Adult Spinal Muscular Atrophy (Sma)
• 6.3. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Spinal Muscular Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Spinal Muscular Atrophy Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nusinersen (Spinraza)
• Onasemnogene Abeparvovec-Xioi (Zolgensma)
• Risdiplam (Evrysdi)
• Antisense Oligonucleotides
• Spinal Muscular Atrophy (SMN2) Splicing Modifiers
• Corticosteroids
• Supportive Medications
• 6.7. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Occupational Therapy
• Respiratory Therapy
• Aquatic Therapy
• Orthotic Support
• Assistive Mobility Devices
• Range-Of-Motion Exercises
• 6.8. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spinal Fusion Surgery
• Scoliosis Correction Surgery
• Orthopedic Surgery
• Gastrostomy Tube Placement
• Tracheostomy
• 6.9. Global Spinal Muscular Atrophy Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Support
• Respiratory Support
• Psychosocial Support And Counseling
• Genetic Counseling
• Stem Cell Therapy

7. Spinal Muscular Atrophy Treatment Market Regional And Country Analysis

• 7.1. Global Spinal Muscular Atrophy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Spinal Muscular Atrophy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Spinal Muscular Atrophy Treatment Market

• 8.1. Asia-Pacific Spinal Muscular Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Spinal Muscular Atrophy Treatment Market

• 9.1. China Spinal Muscular Atrophy Treatment Market Overview
• 9.2. China Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Spinal Muscular Atrophy Treatment Market

• 10.1. India Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Spinal Muscular Atrophy Treatment Market

• 11.1. Japan Spinal Muscular Atrophy Treatment Market Overview
• 11.2. Japan Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Spinal Muscular Atrophy Treatment Market

• 12.1. Australia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Spinal Muscular Atrophy Treatment Market

• 13.1. Indonesia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Spinal Muscular Atrophy Treatment Market

• 14.1. South Korea Spinal Muscular Atrophy Treatment Market Overview
• 14.2. South Korea Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Spinal Muscular Atrophy Treatment Market

• 15.1. Western Europe Spinal Muscular Atrophy Treatment Market Overview
• 15.2. Western Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Spinal Muscular Atrophy Treatment Market

• 16.1. UK Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Spinal Muscular Atrophy Treatment Market

• 17.1. Germany Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Spinal Muscular Atrophy Treatment Market

• 18.1. France Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Spinal Muscular Atrophy Treatment Market

• 19.1. Italy Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Spinal Muscular Atrophy Treatment Market

• 20.1. Spain Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Spinal Muscular Atrophy Treatment Market

• 21.1. Eastern Europe Spinal Muscular Atrophy Treatment Market Overview
• 21.2. Eastern Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Spinal Muscular Atrophy Treatment Market

• 22.1. Russia Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Spinal Muscular Atrophy Treatment Market

• 23.1. North America Spinal Muscular Atrophy Treatment Market Overview
• 23.2. North America Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Spinal Muscular Atrophy Treatment Market

• 24.1. USA Spinal Muscular Atrophy Treatment Market Overview
• 24.2. USA Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Spinal Muscular Atrophy Treatment Market

• 25.1. Canada Spinal Muscular Atrophy Treatment Market Overview
• 25.2. Canada Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Spinal Muscular Atrophy Treatment Market

• 26.1. South America Spinal Muscular Atrophy Treatment Market Overview
• 26.2. South America Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Spinal Muscular Atrophy Treatment Market

• 27.1. Brazil Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Spinal Muscular Atrophy Treatment Market

• 28.1. Middle East Spinal Muscular Atrophy Treatment Market Overview
• 28.2. Middle East Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Spinal Muscular Atrophy Treatment Market

• 29.1. Africa Spinal Muscular Atrophy Treatment Market Overview
• 29.2. Africa Spinal Muscular Atrophy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Spinal Muscular Atrophy Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Spinal Muscular Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Spinal Muscular Atrophy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Spinal Muscular Atrophy Treatment Market Competitive Landscape
• 30.2. Spinal Muscular Atrophy Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Chugai Pharmaceutical Co. Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Spinal Muscular Atrophy Treatment Market Other Major And Innovative Companies

• 31.1. Ionis Pharmaceuticals Inc.
• 31.2. Ultragenyx Pharmaceutical Inc.
• 31.3. Catalyst Pharmaceuticals Inc.
• 31.4. BIOCAD INDIA PRIVATE LIMITED
• 31.5. Cytokinetics Incorporated
• 31.6. Voyager Therapeutics Inc.
• 31.7. Scholar Rock Holding Corporation
• 31.8. Genethon
• 31.9. Exegenesis Bio Inc
• 31.10. NMD Pharma A/S
• 31.11. Biohaven Pharmaceutical Holding Company Ltd
• 31.12. Alcyone Therapeutics Inc.
• 31.13. Vybion Inc.
• 31.14. Apteeus SAS
• 31.15. Biophytis SA

32. Global Spinal Muscular Atrophy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Spinal Muscular Atrophy Treatment Market

34. Recent Developments In The Spinal Muscular Atrophy Treatment Market

35. Spinal Muscular Atrophy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Spinal Muscular Atrophy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Spinal Muscular Atrophy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Spinal Muscular Atrophy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer